HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1302-1308

  Battiwalla, Minoo ^a   Ellis, Kristin ^b   Li, Peigang ^b   Pavletic, Steven Z ^c   Akpek, Gorgun ^d   Hematti, Peiman ^e   Klumpp, Thomas R ^f   Maziarz, Richard T ^g   Savani, Bipin N ^h   Aljurf, Mahmoud D ⁱ   Cairo, Mitchell S ^j   Drobyski, William R ^b   George, Biju ^k   Hahn, Theresa ^l   Khera, Nandita ^m   Litzow, Mark R ⁿ   Loren, Alison W ^o   Saber, Wael ^b   Arora, Mukta ^p   Urbano Ispizua, Alvaro ^q   Cutler, Corey ^r   Flowers, Mary E D ^m   Spellman, Stephen R ^s   more..

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^j NEW YORK MEDICAL COLLEGE   (United States)

^k CHRISTIAN MEDICAL COLLEGE   (India)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ MAYO CLINIC   (United States)

^o HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^q HOSPITAL CLÍNIC   (Spain)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

more..

Author keywords

DR15; Graft versus lymphoma; GVHD; Hematopoietic stem cell transplantation (HSCT); Survival

Indexed keywords

CYCLOSPORIN; HLA DR15 ANTIGEN; METHOTREXATE;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; DONOR; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROPHYLAXIS; RELAPSE; RETROSPECTIVE STUDY; SIBLING; T CELL DEPLETION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA-DR SEROLOGICAL SUBTYPES; HUMANS; INFANT; MALE; MIDDLE AGED; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; YOUNG ADULT;

EID: 84863996073     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.02.011     Document Type: Article

References (25)

1. Mori M., Beatty P.G., Graves M., Boucher K.M., Milford E.L. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997, 64:1017-1027.
2. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: Tissue Antigens. 2003;61:403-407. http://www.allelefrequencies.net.
3. Rugman F.P., Ashby D., Davies J.M. Does HLA-DR predict response to specific immunosuppressive therapy in aplastic anaemia?. Br J Haematol 1990, 74:545-546.
4. Nakao S., Yamaguchi M., Saito M., et al. HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol 1992, 40:239-240.
5. Chapuis B., Von Fliedner V.E., Jeannet M., et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol 1986, 63:51-57.
6. Nakao S., Takamatsu H., Chuhjo T., et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994, 84:4257-4261.
7. Nimer S.D., Ireland P., Meshkinpour A., Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994, 84:923-927.
8. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
9. Marsh J.C., Gordon-Smith E.C. Insights into the autoimmune nature of aplastic anaemia. Lancet 2004, 364:308-309.
10. Song E.Y., Park S., Lee D.S., Cho H.I., Park M.H. Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol 2008, 69:354-359.
11. Shao W., Tian D., Liu C., Sun X., Zhang X. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol 2000, 71:350-352.
12. Maciejewski J.P., Follmann D., Nakamura R., et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001, 98:3513-3519.
13. Feng X., Chuhjo T., Sugimori C., et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004, 104:2425-2431.
14. Oguz F.S., Yalman N., Diler A.S., Oguz R., Anak S., Dorak M.T. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica 2002, 87:772-774.
15. Usman M., Adil S.N., Moatter T., Bilwani F., Arian S., Khurshid M. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. J Pak Med Assoc 2004, 54:251-254.
16. Ilhan O., Beksaç M., Koç H., et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood 1995, 86:2055.
17. Battiwalla M., Hahn T., Radovic M., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 2006, 107:1970-1973.
18. Battiwalla M., Hahn T., McCarthy P.L. HLA DR15 and immunobiologic outcomes. Biol Blood Marrow Transplant 2007, 13:371.
19. Stern M., Passweg J., Tiercy J.M., et al. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1169-1175.
20. Davidson J.A., Tate D.G., Poulton K.V., et al. HLA-DR15, reduced relapse rate and improved survival after HLA identical sibling hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:493-494.
21. Newell L.F., Gooley T., Hansen J.A., Stirewalt D.L., Petersdorf E.W., Deeg H.J. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant 2010, 16:1700-1706.
22. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
23. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958, 53:457-481.
25. Maiers M., Gragert L., Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007, 68:779-788.